Could AI Help During the Current Breast Biopsy Needle Shortage?
Breast biopsy, Breast Screening
Description
A recent recall of the Brevera Breast Biopsy System has contributed to a shortage of stereotactic breast biopsy needles. The FDA has warned that these shortages could continue into early 2027 and has issued guidance to help practices manage limited biopsy resources.
When biopsy resources become constrained, confidence in clinical decision-making becomes even more important.
Why is the biopsy needle shortage creating challenges for breast imaging providers?
The FDA has recommended prioritizing high-risk patients, deferring lower-suspicion lesions where appropriate, and conserving biopsy usage.
As practices work within those constraints, confidence in clinical decision-making becomes increasingly important.
Where could AI play a role?
When we talk about breast AI, much of the discussion focuses on detection.
But in situations like this, it is not only about what gets detected. It is also about helping radiologists make decisions with greater confidence.
How can AI support decision-making?
Understanding whether a finding has changed or remained stable over time is a core part of the decision-making process.
AI tools that help radiologists compare current and prior exams may become increasingly important when evaluating subtle findings.
When practices are being asked to prioritize patients and conserve biopsy resources, that added confidence can become especially valuable.
What does this mean for practices considering AI?
The current biopsy needle shortage highlights how breast AI may support more than detection alone.
As radiologists navigate complex decisions with limited resources, tools that help provide greater confidence and context may become increasingly important.
FAQ
What has caused the current biopsy needle shortage?
The shortage follows the recall of the Brevera Breast Biopsy System and has affected the availability of stereotactic breast biopsy needles.
What has the FDA advised?
The FDA has advised practices to prioritize high-risk patients, defer lower-suspicion lesions where appropriate, and conserve biopsy resources.
Is this article suggesting AI can replace biopsy?
No. The discussion is about how AI may help support clinical decision-making, particularly when resources are constrained.
How could AI help?
AI tools that help radiologists compare current and prior exams may support evaluation of subtle findings and contribute to greater confidence in decision-making.
